Results 81 to 90 of about 2,821 (202)
Citation: 'antimuscarinic' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.15465 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms. Requests for commercial
openaire +1 more source
Biological and Pharmaceutical Bulletin, 2007 Solifenacin succinate [YM905; (3R)-1-azabicyclo[2.2.2]oct-3-yl(1S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate monosuccinate] is a new muscarinic receptor antagonist developed for the treatment of overactive bladder. The aim of the present study was to evaluate the antimuscarinic properties of solifenacin and to compare the results with those ...
Ohtake, Akiyoshi +10 more
openaire +3 more sources
Adherence and persistence to oral medication in patients with overactive bladder (OAB) in a real-world setting – a systematic literature review. [PDF]
, 2018 Purpose To evaluate persistence and adherence of oral pharmacotherapy used in the treatment of overactive bladder (OAB) in a real-world setting. Materials and methods Systematic literature searches of six electronic publication databases were performed ...
Smith, Philip +5 more
core +1 more source
Medical management of overactive bladder
Indian Journal of Urology, 2010 Overactive bladder (OAB), as defined by the International Continence Society, is characterized by a symptom complex including urinary urgency with or without urge incontinence, usually associated with frequency and nocturia. OAB syndrome has an incidence
Sarvpreet S Ubee +2 more
doaj +1 more source
How do detrusor responses to clinical antimuscarinic medications vary between differently aged porcine bladders? [PDF]
Antimuscarinics are the first line medications for overactive bladder (OAB) patients, with a mechanism involving the inhibition of detrusor spontaneous contractions during the filling phase.
Chess-Williams, Russ +2 more
core +1 more source
A Nordic registry-based study of drug treatment patterns in overactive bladder patients
, 2019 Aim: To describe treatment patterns in Denmark, Norway and Sweden for patients receiving overactive bladder (OAB) pharmacotherapy. Methods: This was a prospective, multinational, registry-based study involving three nationwide prescribed drug registries (
Hjalmar A. Schiotz (6840575) +4 more
core +2 more sources
ContinenceAntimuscarinics have long been the cornerstone of treatment for overactive bladder (OAB), with their use spanning decades. This paper reviews the pharmacological properties, historical use, clinical efficacy, and challenges associated with ...
D. Carolina Ochoa +2 more
doaj +1 more source
Re: Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder
Journal of Urological Surgery, 2016 EDITORIAL COMMENT Overactive bladder (OAB) is a highly prevalent disorder in the pediatric population. This event negatively affects and impairs children’s development. Antimuscarinics are the mainstay pharmacological management of OAB, but their side
Sinharib Çitgez
doaj +1 more source
, 2020 OBJECTIVE: The differential muscarinic receptor selectivity could cause selective antimuscarinics to offer advantages over non-selective agents with respect to adverse effects.
Rajender R. Aparasu +9 more
core +1 more source
BMC Geriatrics, 2017 Background To examine factors predicting type of bladder antimuscarinics (BAM) initiated in nursing home (NH) residents. Methods Incident BAM initiators following NH admission were identified by constructing a retrospective cohort from Medicare files and
Daniela C. Moga +3 more
doaj +1 more source